top of page
Mark Stockdale
Director of Strategic Alliances at Asimov
Mark began his career in drug discovery, investigating resistance mechanisms to antibiotics and anti-virals. In 2008, Mark transitioned into cell-based tools for drug development, leading the team developing new mammalian host cell lines for the bioprocess industry at Horizon Discovery (now Revvity). At Asimov, his responsibilities include finding new opportunities and technologies to support development of clinical assets, whether that is synthetic biology techniques, in silico models, or new expression hosts.



Speakers
bottom of page